Adenosine and calcium antagonists demonstrate equivalent efficacy in the conversion of stable supraventricular tachycardia (SVT) to sinus rhythm. The choice between them is not based on success rate, but on their different safety and pharmacokinetic profiles. Adenosine is the first-line drug recommended by clinical guidelines due to its ultra-short half-life of less than 10 seconds, which ensures that its common adverse effects (chest pain, dyspnea) are extremely brief and self-limiting. Its action is almost immediate, causing a transient block of the AV node that effectively interrupts the...